BioSpace News Archive

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company primarily focused on leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, today announced the filing of a premarket notification 510(k) to the U.S. Food and Drug Administration (FDA) for its novel CellFX nsPFA Cardiac Clamp.

NovAccess Global Inc., a biomedical company developing novel immunotherapies for brain tumor patients, announced it entered into a securities purchase agreement with an affiliate of Sumner Global LLC for a total financing of $10.7 million.

Catheter Precision, Inc. announced that Great Britain and the European Market have allowed two new patents, further strengthening the company’s IP position for its LockeT product line.

ValGenesis, Inc. announced that a leading Spanish pharmaceutical company selected ValGenesis VLMS – the industry’s most trusted electronic validation lifecycle management system – to digitize its corporate validation process.

Inspira Technologies OXY B.H.N Ltd., a pioneer in life support technology with a vision to supersede traditional mechanical ventilators, has announced the signing of a non-binding Letter of Intent with Northwestern Memorial Hospital in Chicago, Illinois.

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals”, (NRx), a clinical-stage biopharmaceutical company today announced that it has been selected to give the keynote address entitled “Ketamine for Suicidal Depression: The Benefits are Clear, But So are the Risks,” at the upcoming Sachs Neuroscience Innovation Forum in San Francisco, CA on January 7, 2024.

BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCF) (FSE: 8MV) (“BioHarvest” or the “Company”) is pleased to announce that it has closed the second and final tranche of its non-brokered private placement of convertible notes

Biosenta Inc. (CSE: ZRO) (the “Company” or “Biosenta”), is pleased to announce that it has closed its private placement for gross proceeds of $500,000 (the “Offering”), as previously announced on December 15, 2023.

Specialty cancer diagnostics company Precipio, Inc. is pleased to welcome Christina Valauri to its board of directors effective Jan 1st, 2024.

BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) (“BioMark” or the “Company”), an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers